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Highlights 
 Genotyping for four polymorphic sites in the VDR gene in patients with Parkinson’s 
disease. 
 Association was detected between FokI C polymorphism and Parkinson’s disease. 
 No association could be detected between ApaI, BsmI, TaqI polymorphisms and 
Parkinson’s disease. 
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Abstract 
Vitamin D receptor (VDR) gene encodes a transcription factor that influences calcium 
homeostasis and immunoregulation, and may play a role in neurological disorders including 
Parkinson's disease (PD). The investigations of the association between VDR and PD in 
different populations revealed various results. In a present study 100 PD patients and 109 
healthy controls from the Hungarian population were genotyped for four polymorphic sites 
(BsmI, ApaI, FokI and TaqI) in the VDR gene. The polymorphisms were determined by 
polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP). Our 
results demonstrate an association between the FokI C allele and PD; the frequency of the C 
allele was significantly higher in PD patients than in controls, suggesting that this 
polymorphism may have a role in the development of PD in these patients. 
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1. Introduction 
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders. The 
characteristic neuropathological features are the presence of Lewy bodies and the loss of 
dopaminergic cells in the substantia nigra pars compacta, but the precise pathomechanism is 
still not fully understood. The most common concepts are related to the genetic background 
and environmental effects [5]. Indeed, a number of genetic risk factors and gene-environment 
interactions have been implicated in the pathogenesis of PD [13, 14, 19-21, 24, 25, 29, 37]. 
Vitamin D, as an environmental factor, has been the subject of various studies on different 
neurological disorders, from which it has emerged that a vitamin D deficiency is associated 
with an increased risk of many diseases, including schizophrenia, autism, multiple sclerosis, 
Alzheimer’s disease and PD [1, 3, 4, 7, 9, 22, 26-28, 30, 33, 35]. 
In humans, the majority of vitamin D is synthesized via the cleavage of a cholesterol 
metabolite in the epidermis by UVB, with further metabolism to the primary circulating form 
of vitamin D, 25-hydroxyvitamin D (25OHD), in the liver. This compound circulates in the 
blood in a form bound to vitamin D binding protein and in the kidneys 25OHD is metabolized 
by 1-α-hydroxylase to its active form, 1,25-dihydroxyvitamin D (1,25OHD). 1,25OHD binds 
to vitamin D receptors (VDRs) and influences calcium homeostasis, neurotrophic signalling, 
immunoregulation, cell growth and differentiation [8, 16, 17]. Both 1-α-hydroxylase and 
VDRs are expressed in numerous body tissues, including the brain [10].  
The VDR gene encodes a nuclear transcription factor. The human gene is localized to 
12q12 and various polymorphisms have been reported in it [38]. The level of vitamin D in PD 
has been analysed in number of studies. A Japanese population exhibited a higher incidence 
of hip fractures and  lower serum levels of 25OHD in PD patients as compared with the 
healthy controls [34, 35], observations that were confirmed in a Caucasian population [9]. The 
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serum 25OHD level correlated negatively with the severity of PD, measured in terms of the 
Hoehn &Yahr stage and the Unified Parkinson’s Disease Rating Scale (UPDRS) [34-36]. 
Whereas Sato et al. [34] reported a negative correlation between the 1,25OHD level and the 
UPDRS score, Suzuki et al. [36] could not confirm this finding. 
However, only limited data are available regarding the association between VDR 
polymorphisms and PD. Suzuki et al. [36] found that FokI CC genotype was associated with 
milder forms of PD in a Japanese population. Furthermore, an association between the BsmI 
bb genotype and PD was demonstrated in a Korean population [18]. A recent genome-wide 
association study revealed the association of VDR polymorphisms with the risk of PD and the 
age at onset in a Caucasian population [6]. In a Chinese study it was described that FokI C 
allele associates with an increased risk of PD as well as early-onset PD [12]. 
The study we report here related to whether the known VDR gene polymorphisms 
ApaI, FokI, TaqI and BsmI are associated with PD in the Hungarian population, which 
belongs to the Caucasian race. 
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2. Material and methods 
2.1 Subjects 
100 idiopathic PD patients (mean age: 66.4±9.3 yr; 44 men and 56 women) were 
enrolled. The patients were evaluated by movement disorders specialists, who confirmed the 
diagnosis of idiopathic PD. Secondary forms of parkinsonism were excluded. The age at onset 
was determined from the medical records and the cases were categorized as early-onset 
(diagnosed ≤60 yr) or late-onset (diagnosed >60 yr) PD (Table 1). The Park2 and LRRK2 
mutations were not present. 
The control group comprised 109 healthy individuals (mean age: 64.0±8.2 yr; 54 men 
and 55 women) who had no history of neurological or psychiatric disorders (Table 1). The 
patients and healthy controls, all of Hungarian origin, were selected from the Department of 
Neurology and Department of Medical Microbiology and Immunobiology at the University of 
Szeged. The study was approved by the Ethics Committee of the Faculty of Medicine, 
University of Szeged. All study participants gave their written informed consent, in 
accordance with the Declaration of Helsinki.  
 
Table 1. 
Characteristics of PD patients and healthy controls 
 PD group (%) Control group (%) 
No. 100 109 
Age (mean±SEM) 66.4±9.3 64.0±8.2 
Age at onset ≤ 60 
Age at onset > 60 
52 (52) 
48 (48) 
 
Gender  
Male 
Female 
 
44 (44) 
56 (56) 
 
54 (49.5) 
55 (50.5) 
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2.2 DNA isolation 
Genomic DNA was isolated from the peripheral blood by a standard desalting method 
[23], and stored at –20°C until further use.  
The VDR polymorphisms were determined by polymerase chain reaction (PCR) 
techniques in a thermal cycler (Applied Biosystems 2720 Thermal Cycler, Applied 
Biosystems, Foster City, CA, USA) and restriction fragment-length polymorphism (RFLP). 
2.3 Genotyping 
For amplification of the FokI C/T polymorphism (rs10735810) the following primers 
were used [15]: forward primer 5’-AGC TGG CCC TGG CAC TGA CTC TGC TCT-3’ and 
reverse primer 5’-ATG GAA ACA CCT TGC TTC TTC TCC CTC-3’. The PCR 
amplification was carried out with the following cycling parameters: 95°C for 5 min, and then 
30 cycles of 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s, and finally 72°C for 7 min. The 
PCR products were digested with the FokI restriction enzyme (Fermentas, Vilnius, Lithuania) 
at 55°C for 3 h. The digested products were separated by agarose gel electrophoresis. The 
genotypes were defined as CC (265 bp), TT (169 and 96 bp) or CT (265, 169 and 96 bp). 
The BsmI A/G polymorphic site of intron 8 (rs1544410) was amplified with 
previously described primers [18]: forward primer 5’-CAA CCA AGA CTA CAA GTA CCG 
CGT CAG TGA-3’ and reverse primer 5’-AAC CAG CGG GAA GAG GTC AAG GG-3’. 
The PCR conditions were as follows: 95°C for 10 min, 95°C for 30 s, 59°C for 30 s and 72°C 
for 50 s for 35 cycles, and finally 72°C for 10 min. The PCR products were digested with the 
restriction enzyme Mva12691 (Fermentas, Vilnius, Lithuania) at 37°C overnight. Fragments 
were separated by electrophoresis in 2% stained agarose gels and visualized in UV light. The 
genotypes were defined as AA (825 bp), GG (650 and 175 bp) or AG (825, 650 and 175 bp). 
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PCR amplification of the polymorphic TaqI T/C site (rs731236) was performed with 
the following primers [31]: forward 5’-CAG AGC ATG GAC AGG GAG CAA-3’ and 
reverse 5’-CAC TTC GAG CAC AAG GGG CGT TAG C-3’. The PCR conditions were 
identical to those for the BsmI polymorphism. The PCR products were digested with the TaqI 
restriction enzyme (Fermentas, Vilnius, Lithuania) at 65°C for 3 h and fragments were 
analysed by electrophoresis in 2% agarose gel. The absence of the TaqI restriction site on 
both alleles (TT) led to the 501 bp fragment, whereas the presence of the restriction site on 
both alleles (CC) yielded bands of 295 and 206 bp. The presence of the 501, 295 and 206 bp 
fragments reflected the TC heterozygotes. 
The ApaI G/T polymorphic site (rs7976091) was amplified with previously described 
primers [32]: forward primer 5’-CAA CCA AGA CTA CAA GTA CCG CGT CAG TGA-3’ 
and reverse primer 5’-CAC TTC GAG CAC AAG GGG CGT TAG C-3’ The PCR conditions 
were: 95°C for 10 min, followed by 35 cycles of 95°C for 30 s, 59°C for 30 s and 72°C for 2 
min, and finally 72°C for 7 min. The PCR products were incubated with the ApaI restriction 
enzyme (Fermentas, Vilnius, Lithuania) at 37°C overnight. The genotypes were defined as TT 
(absence of restriction site, one band at 2000 bp), TG (heterozygote, three bands at 2000, 
1700 and 300 bp) and GG (presence of the restriction site, two bands at 1700 and 300 bp). 
2.4 Statistical analysis 
All statistical analyses were performed with the SPSS Statistics 17.0 software (SPSS 
Inc., Chicago, IL, USA). The difference in genotype frequencies was analysed by using the 
Fisher’s exact test or the χ2 test. The associations between the genotypes and the PD were 
estimated via the odds ratio (OR), with a 95% confidence interval (CI) (95% CI). A p value of 
less than 0.05 was considered statistically significant. The observed FokI, BsmI, ApaI and 
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TaqI genotype frequencies were in accordance with the Hardy–Weinberg equilibrium in both 
the patients and the controls. 
3. Results 
3.1 VDR FokI polymorphism 
The distributions of FokI restriction site genotypes in the PD patients and the controls 
are shown in Table 2. There was a significant difference in genotypes between the PD patients 
and the healthy controls (χ2 = 6.7; p = 0.035). The frequency of genotype with C (CC+CT) 
was significantly higher among the patients with PD relative to the controls: OR = 2.677 and 
95% CI = 1.214-5.91, p = 0.015 for CC+CT vs. TT. Moreover, the C allele showed a 
significant association with PD group (OR = 1.615, 95% CI = 1.087-2.399, p = 0.017). There 
was no difference between the FokI polymorphism and gender in PD group, and no 
significant association was found between this polymorphism and the age at onset (Table 3).  
Table 2.  
VDR FokI genotypes and allele frequencies in the PD patients and the controls 
 Genotype  Allele frequency 
 CC (%) CT (%) TT (%) p C (%) T (%) p 
PD patients 42 (42) 48 (48) 10 (10) 
0.035 
132 (66) 68 (34) 
0.017 
Control 35 (32.1) 49 (45) 25(22.9) 119 (54.6) 99 (45.4) 
 
Table 3.  
Relationship between age at onset and gender in the PD patients as a function of the VDR 
FokI genotyping 
 CC (%)  CT (%) TT (%) p 
Age at onset 
≤60 yr 
>60 yr 
 
22 (42.3) 
20 (41.7) 
 
24 (46.2) 
24 (50) 
 
6 (11.5) 
4 (8.3) 
 
0.841 
Gender  
Male 
Female 
 
18 (40.9) 
24 (42.9) 
 
22 (50) 
26 (46.4) 
 
4 (9.1) 
6 (10.7) 
 
0.958 
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3.2 VDR BsmI polymorphism 
There was no significant difference in the BsmI genotypic distribution (OR = 0.890, 
95% CI = 0.478-1.654, p = 0.753 for GG vs. AA+AG) and allele frequency (OR = 0.977, 
95% CI = 0.665-1.434, p = 0.905) between the PD patients and the healthy controls. The 
BsmI genotypic distribution, the allele frequency, the male to female ratio and the age at onset 
of the PD patients are presented in Table 4. 
Table 4.  
VDR BsmI genotypes and allele distributions in patients with PD and controls 
Genotype Allele frequency 
 AA (%) AG (%) GG (%) p A (%) G (%) p 
PD patients 
Controls 
24 (24) 
25 (22.9) 
49 (49) 
57 (52.3) 
27 (27) 
27 (24.8) 
0.902 
97 (48.5) 
107 (49) 
103 (51.5) 
111 (51) 
0.905 
Age at onset 
≤60 yr 
>60 yr 
 
9 (17.3) 
15 (31.3) 
 
27 (51.9) 
22 (45.8) 
 
16 (30.8) 
11 (22.9) 
 
0.261 
   
Gender  
Male 
Female 
 
7 (15.9) 
17 (30.4) 
 
22 (50) 
27 (48.2) 
 
15 (34.1) 
12 (21.4) 
 
0.161 
   
 
3.3 VDR TaqI polymorphism 
The frequencies of the TaqI genotype in the PD group and the controls were similar 
(OR = 0.840, 95% CI = 0.399-1.767, p = 0.646 for TT+TC vs. CC) and we did not find 
differences in allele distribution (OR = 0.802, 95% CI = 0.540-1.190, p = 0.273). There was 
no significant difference in the male to female ratio and the age at onset in the various TaqI 
polymorphism subgroups (Table 5). 
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Table 5.  
VDR TaqI genotypes and allele frequencies in patients with PD and controls 
 Genotype  Allele frequency 
 TT (%) TC (%)  CC (%) p T (%) C (%) p 
PD patients 
Controls 
35 (35) 
47 (43.1) 
48 (48) 
46 (42.2) 
17 (17) 
16 (14.7) 
0.485 
118 (59) 
140 (64.2) 
82 (41) 
78 (35.8) 
0.273 
Age at onset 
≤60 yr 
>60 yr 
 
22 (42.3) 
13 (27.1) 
 
23 (44.2) 
25 (52.1) 
 
7 (13.5) 
10 (20.8) 
 
0.265 
   
Gender 
Male 
Female 
 
18 (40.9) 
17 (30.4) 
 
20 (45.5) 
28 (50) 
 
6 (13.6) 
11 (19.6) 
 
0.528 
   
 
3.4 VDR ApaI polymorphism 
The ApaI genotype frequencies (OR = 1.352, 95% CI = 0.654-2.796, p = 0.466 for GG 
vs. TT+TG) and the allele distribution (OR = 1.177, 95% CI = 0.793-1.748, p = 0.417) were 
similar in the healthy controls and the patients with PD (Table 6). There was no statistically 
significant association between the ApaI polymorphism and the age at onset in PD patients, 
and no significant difference was found between this polymorphism and gender in the PD 
group. 
Table 6. 
VDR ApaI genotypes and allele frequencies in the PD patients and the controls 
Genotype  Allele frequency 
 TT (%) TG (%) GG (%) p T (%) G (%) p 
PD patients 
Controls 
42 (42) 
42 (38.5) 
43 (43) 
46 (42.2) 
15 (15) 
21 (19.3) 
0.691 
127 (63.5) 
130 (59.6) 
73 (36.5) 
88 (40.4) 
0.417 
Age at onset 
≤60 yr 
>60 yr 
 
18 (34.6) 
24 (50) 
 
23 (44.2) 
20 (41.7) 
 
11 (21.2) 
4 (8.3) 
 
0.130 
   
Gender 
Male 
Female 
 
13 (29.5) 
29 (51.8) 
 
22 (50) 
21 (37.5) 
 
9 (20.5) 
6 (10.7) 
 
0.07 
   
 
4. Discussion 
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This work involved a study of VDR polymorphism in PD patients among Hungarians. 
Earlier reports revealed that 25OHD levels were decreased in PD patients in Japanese and 
Caucasian populations [9, 34, 35] and demonstrated a higher incidence of osteoporosis in PD 
patients of both genders, with a decreased bone mass index and a reduced bone mineral 
density [11, 34]. Overall, it has been clearly shown that the vitamin D metabolism is affected 
in PD patients. 
Differences have also been demonstrated in the VDR polymorphisms in PD in 
Japanese, Korean, Chinese and Caucasian populations [6, 12, 18, 36]. 
Our results have indicated a significant difference in the FokI genotype distribution 
between PD and controls in Hungarian population; the frequency of the C allele was 
significantly higher in PD patients than in the healthy control group, suggesting that the C 
allele may have a role in the development of PD.  
Previously, a Japanese and a Chinese study detected difference in this polymorphism 
between healthy subjects and PD patients. In Japan, FokI CC genotype was associated with 
milder forms of PD [36].  Han et al. [12] suggested that FokI C allele might be a risk factor 
for sporadic PD development.  
FokI polymorphism is located in exon 2 at the 5′ coding region of the gene. This 
polymorphism results in different translation initiation sites:  if the VDR gene contains C 
allele, the protein will be three amino acids shorter. Difference in length may result in altered 
VDR function [2, 38]. 
BsmI, ApaI and TaqI polymorphisms are located in the 3’-end region of the VDR 
gene, which do not result in changes in the amino acid sequence of the VDR [38]. We did not 
identify significant associations with these VDR polymorphisms. A Korean study detected 
difference in the genotype frequency of BsmI polymorphism between healthy subjects and PD 
patients; the bb genotype in that study was more common in Korean PD patients than in 
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controls [18]. No difference in BsmI polymorphism was identified in Japanese patients [36], 
where the FokI CC genotype displayed a strong association with the milder forms of PD.  
 Our data demonstrated no significant associations between VDR ApaI polymorphism 
and PD, whereas the ApaI polymorphism was associated with the early-onset form of PD in 
American Caucasians. Interestingly, there was no association between FokI polymorphism 
and PD patients among American Caucasians, reflecting differences in ethnicity among 
Caucasians [6].  
These diverse data suggest that the Caucasian population is not homogeneous in this 
respect. We did not detect an association between the age at onset, the male-female ratio and 
the VDR polymorphisms in the PD group. The differences between the results of the various 
authors must be interpreted with regard to the facts that the study populations and sample 
sizes differed, with the additional possibility of certain ethnic variations. 
 
As far as we are aware, this is the first report on the potential correlation between a 
VDR polymorphism and PD from a European country. We conclude overall that the C allele 
of the VDR FokI polymorphism may be associated with PD in a Caucasian population. 
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